A randomized, double‐blind, placebo‐controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease
Clinical and Translational Science · 2025
DOI: 10.1111/cts.13901 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Darren Bentley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Ltd., Sheffield, UK. Hauptthemen laut MEDLINE: Celiac Disease, Cathepsins, Glutens. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Celiac disease is a chronic, immune‐mediated enteropathy with symptoms triggered by exposure to dietary gluten in genetically predisposed individuals. The only available management option is lifelong adherence to a gluten‐free diet. This randomized, double‐blind, placebo‐controlled, parallel‐group, single‐center study tested the effects of the cathepsin S inhibitor RO5459072 on the immune response to a 13‐day gluten challenge in 19 participants with celiac disease ( ClinicalTrials.gov : NCT02679014). Nine participants in the RO5459072 arm received 100 mg study drug b.i.d. (200 mg daily); 10 received a placebo. The primary end point was the number of responders to the gluten challenge (defined as individuals with an increase in the number of gliadin‐specific, IFNγ‐secreting T cells detected using an ELISPOT assay). However, there was a weak response to the gluten challenge across both arms. Few participants had an increase in gliadin‐specific, IFNγ‐secreting T cells, and the antigen‐specific responses (anti‐tTG and anti‐DGP antibodies) were weaker than expected in both arms. Therefore, the primary end point was not met, although the study was underpowered to detect a treatment effect under these circumstances. Pharmacodynamic findings suggested that RO5459072 had some beneficial effects. Fewer participants in the RO5459072 arm exhibited gliadin‐specific IFNγ‐secreting T cells after 6 days' gluten intake. Participants in the RO5459072 arm also showed decreased intestinal permeability, and a decrease in the number of circulating B cells, CD4+ and CD8+ T cells compared to baseline. Nevertheless, the absence of clear effects on the response to a gluten challenge indicates that inhibition of cathepsin S may not be an effective treatment strategy for celiac disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Certara UK Ltd., Sheffield, UK.
- Bristol Myers Squibb, Lawrence Township, New Jersey, USA.
- F. Hoffmann-La Roche, Basel, Switzerland.
- Hammersmith Medicines Research, London, UK.
ORCID-Profile: Darren Bentley, Bernhard Reis, Malcolm Boyce
Zitieren
APA
Bentley, D., Mannino, M., Manchester, M., Teixeira, P. C., Reis, B., Boyce, M., & Nagel, S. (2025). A randomized, double‐blind, placebo‐controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease. Clinical and Translational Science. https://doi.org/10.1111/cts.13901
Vancouver
Bentley D, Mannino M, Manchester M, Teixeira PC, Reis B, Boyce M, et al. A randomized, double‐blind, placebo‐controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease. Clinical and Translational Science. 2025. doi:10.1111/cts.13901
BibTeX
@article{Bentley2025,
author = {Bentley, Darren and Mannino, Marie and Manchester, Marianne and Teixeira, Priscila Camillo and Reis, Bernhard and Boyce, Malcolm and Nagel, Sandra},
title = {A randomized, double‐blind, placebo‐controlled, multiple dose, parallel study to investigate the effects of a cathepsin S inhibitor in celiac disease},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.13901}
}
EUVIMED